Home › Squamous Cell Carcinoma ng Ulo at Leeg › Utah
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Utah
21 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa Utah.
Mga Lungsod sa Utah
Opisyal na teksto ng pag-aaral (English)
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07085091A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Huntsman Cancer Institute, Salt Lake City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- University of Utah Huntsman Cancer Institute, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06385080BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- START Center for Cancer Research, West Valley City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07109726ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06465069Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT05985655A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06330064A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Utah Cancer Specialists, Salt Lake City
- University of Utah Health Huntsman Cancer Hospital, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT03526835A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START Mountain Region, LLC, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT07503808Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT07517198High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Farmington Health Center, Farmington
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 11, 2026 · NCT06992427Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT07044635Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 18, 2026 · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Dis 11, 2025 · NCT03556228Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.